A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency

Kazuaki Taguchi, Toshikazu Miyakawa, Takafumi Ohmura, Momoko Horio, Yoshihisa Anraku, Tatsuya Okada, Hiroshi Mizuta, Hideyuki Saito, Tatsuya Kawaguchi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The optimal dosage of linezolid to avoid hematologic toxicity is unknown. We report the case of an 87-y-old woman with renal insufficiency who developed a surgical site infection with refractory methicillin-resistant Staphylococcus aureus. The standard dosage of linezolid (1200 mg daily) was not initially tolerated by the patient due to severe thrombocytopenia, but she was successfully treated when the dose was reduced by half (600 mg daily) based on a population pharmacokinetic-pharmacodynamic model. Appropriate dose adjustments can be made to optimize linezolid therapy especially in cases with preexisting renal dysfunction.

Original languageEnglish
Pages (from-to)77-80
Number of pages4
JournalScandinavian Journal of Infectious Diseases
Volume45
Issue number1
DOIs
Publication statusPublished - 2013 Jan 1
Externally publishedYes

    Fingerprint

Keywords

  • Linezolid
  • Renal insufficiency
  • Thrombocytopenia

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Microbiology (medical)
  • Infectious Diseases

Cite this